Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8mL dose.

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and ...

Peptide therapy enhances targeted medicine, utilizing specific peptides for effective treatment of cancer, metabolic disorders, and neurodegenerative diseases.

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...

TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...